ALDA Pharmaceuticals Closes Private Placement for Gross Proceeds of $200,000
14 Gennaio 2011 - 12:44AM
Marketwired
ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCQB: APCSF) (the
"Company") is pleased to announce that it has closed the private
placement announced December 8th, 2010. The Company has issued a
total of 2,000,000 Units at a price of $0.10 per Unit for gross
proceeds of $200,000. Each Unit consists of one common share of
ALDA and one non-transferable share purchase warrant entitling the
holder to acquire one additional common share of ALDA at a price of
$0.20 per common share until January 12, 2013 subject to a forced
exercise provision attached to each warrant commencing on the day
following the expiry of any applicable hold period on the
underlying Common Shares, stating that if, for ten consecutive
trading days, the closing price of the listed shares of the Company
exceeds $0.40 then the exercise period of the warrants will be
reduced to a period of 10 days following such trading days.
Insiders of ALDA subscribed for 1,670,000 Units on the same
terms as arm's length investors, constituting a related party
transaction pursuant to Multilateral Instrument 61-101 and TSX
Venture Exchange Policy 5.9. Such Insider participation was exempt
from the requirement to obtain an independent valuation pursuant to
Section 5.5(b) of MI 61-101 and the requirement to obtain minority
shareholder approval pursuant to Section 5.7(1)(b) of MI
61-101.
All securities issued with respect to the private placement are
subject to a hold period expiring on May 13, 2011 in accordance
with the policies of the TSX Venture Exchange and applicable
Canadian securities laws.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control
therapeutics derived from its patented T36® technology. The company
trades on the TSX Venture Exchange under the symbol APH and on the
OTCQB under the symbol APCSF. The Company was the Official Supplier
to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010
Paralympic Winter Games and is the Official Supplier to the
Canadian Olympic Committee, the 2010 Canadian Olympic Team and the
2012 Canadian Olympic Team for antiseptic hand sanitizer,
disinfectant and disinfectant cleaning products. The Company was
also selected as one of the TSX Venture 50 companies in the
Technology and Life Sciences sector for 2010.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.
The Units, common shares, warrants and the common shares
issuable upon exercise of the warrants have not been registered
under the United States Securities Act of 1933 (the "Act") and may
not be offered or sold absent registration under the Act or an
applicable exemption from the registration requirements thereof.
This news release does not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such jurisdiction or
an exemption therefrom.
Cautionary Note Regarding Forward-looking Statements:
Information in this press release that involves ALDA's
expectations, plans, intentions or strategies regarding the future
are forward-looking statements that are not facts and involve a
number of risks and uncertainties. ALDA generally uses words such
as "outlook", "will", "could", "would", "might", "remains", "to
be", "plans", "believes", "may", "expects", "intends",
"anticipates", "estimate", "future", "plan", "positioned",
"potential", "project", "remain", "scheduled", "set to", "subject
to", "upcoming", and similar expressions to help identify
forward-looking statements. The forward-looking statements in this
release are based upon information available to ALDA as of the date
of this release, and ALDA assumes no obligation to update any such
forward-looking statements. Forward-looking statements believed to
be true when made may ultimately prove to be incorrect. These
statements are not guarantees of the future performance of ALDA and
are subject to risks, uncertainties and other factors, some of
which are beyond its control and may cause actual results to differ
materially from current expectations.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contacts: ALDA Pharmaceuticals Corp. Scott Young Investor
Relations 604-377-5781 or 604-521-8300 Ext 203
scott_young@aldacorp.com www.aldacorp.com
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Aphria Inc. (TSXV:APH)
Storico
Da Giu 2023 a Giu 2024